In situ generation of nitidine by photooxidation and its application in preparation of cell probes and anticancer drugs
By reacting dihydrogen two-sided acne with oxygen under light, it solves the complexity of traditional photo-activated chemotherapy and toxic by-products, and achieves efficient selective killing of cancer cells and high spatial resolution treatment, reducing the number of patients with reduced levels of cancer cells. toxicity to normal cells.
Patent Information
- Application Number
- CN202310258439.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-03-16
AI Technical Summary
Traditional photoactivation chemotherapy methods are complex and easy to produce toxic by-products, which limits its application in anti-cancer treatment. The existing alkaloids are highly toxic to normal tissues and are difficult to achieve spatially selective activation.
By reacting dihydrogen and oxygen with oxygen to react with dihydrogen, the synergistic effect of photoactivation chemotherapy and photodynamic therapy is achieved, simplifying the preparation process and improving the anti-cancer efficiency.
This method achieves selective killing of cancer cells, reduces toxicity to normal cells, improves biocompatibility and treatment efficiency, and has important medical application value.
Smart Images

Figure CN116375721B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical materials, and in particular relates to in-situ generation of nitidine by photo-oxidation and application thereof in preparation of cell probes and anticancer drugs. Background Art
[0002] Alkaloids with anticancer activity have broad clinical application prospects, but they are usually highly toxic to normal tissues or cells, which seriously limits their application. In order to reduce the toxic side effects on normal tissues or organs, it is urgent to establish a method to spatially selectively activate the anticancer activity of alkaloids.
[0003] Photoactivated chemotherapy has the advantage of high spatiotemporal resolution and can selectively kill cancer cells by controlling the treatment area through light irradiation. However, traditional photoactivated chemotherapy usually requires the modification of photo-cleavable groups on chemotherapy drugs, which not only has cumbersome synthesis steps but also easily generates toxic byproducts, which seriously limits its application. Therefore, it is urgent to develop photoactivated chemotherapy strategies with good biocompatibility. Summary of the invention
[0004] In order to solve the above problems, the present invention proposes for the first time a new method for using nitidine with photodynamic activity to effectively kill cancer cells through the generation of reactive oxygen species. This method can synergistically utilize light-activated chemotherapy and photodynamic therapy, which will further improve the precise anti-cancer efficiency of alkaloids.
[0005] At the same time, the present invention also proposes for the first time a method for generating nitidine in situ by light activation, and a method for synergistically killing cancer cells by utilizing the chemotherapy and photodynamic therapy activities of the nitidine generated in situ. The present invention reacts dihydronitidine with oxygen under light conditions to obtain a nitidine compound having chemotherapy toxicity and photodynamic therapy activity, and the method is simple and efficient.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] The present invention provides a method for light-activated in-situ generation of nitidine, which comprises dispersing dihydronitidine represented by formula (I) in a medium, and then placing it in oxygen or air, and oxidizing it under light to obtain the nitidine.
[0008]
[0009] In one embodiment of the present invention, the reaction route of the preparation method is:
[0010]
[0011] Wherein, X is an anion provided by the medium.
[0012] In one embodiment of the invention, the medium comprises water or intracellularly.
[0013] In one embodiment of the present invention, the oxygen content in the air is not less than 21%. It is further preferred that the oxygen content in the air is greater than or equal to 40%; it is further preferred that the oxygen content in the air is greater than or equal to 60%; it is further preferred that the oxygen content in the air is greater than or equal to 80%; it is further preferred that the above reaction is carried out in oxygen.
[0014] In one embodiment of the present invention, the light is ultraviolet light or purple light; the intensity of the light is 1 to 20 mW / cm 2 .
[0015] The present invention also provides the use of dihydronitidine represented by formula (I) in the preparation of cell fluorescent probes.
[0016]
[0017] Among them, dihydronitidine generates nitidine under light irradiation, and nitidine aggregates in the cell nucleus to form a cell fluorescent probe for fluorescence imaging.
[0018] The present invention also provides the use of dihydronitidine represented by formula (I) in the preparation of anticancer drugs with photoactivated chemotherapy and photodynamic therapy functions.
[0019]
[0020] In one embodiment of the present invention, the principle process of the above application includes: using the dihydronitidine shown in formula (I) as a photoactivated prodrug, undergoing photooxidative dehydrogenation reaction under light irradiation to generate nitidine, thereby achieving synergistic killing of cancer cells through chemotherapy and photodynamic therapy activity.
[0021] In one embodiment of the present invention, cancer includes: lung cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin melanoma or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, gallbladder cancer, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, pancreatic cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue carcinoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer or ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system (CNS) cancer, primary central nervous system lymphoma, spinal axis cancer, brain stem glioma, pituitary adenoma, etc.
[0022] In one embodiment of the present invention, the anticancer drug also includes pharmaceutical excipients; the pharmaceutical excipients are selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids and release retardants.
[0023] In one embodiment of the present invention, the anticancer drug further comprises a pharmaceutical carrier; the pharmaceutical carrier is selected from microcapsules, microspheres, nanoparticles and liposomes.
[0024] In one embodiment of the present invention, the dosage form of the anticancer drug is selected from the group consisting of injection, lyophilized powder for injection, suspension, implant, embolic agent, capsule, tablet, pill and oral solution.
[0025] Compared with the prior art, the present invention has the following advantages and effects:
[0026] The compound used in the present invention, dihydronitidine, can achieve the advantages of photoactivated chemotherapy and photodynamic therapy under the condition of light irradiation, and can achieve selective killing of cancer cells through light control.
[0027] The present invention uses dihydronitidine with good biocompatibility as a substrate, and generates nitidine in situ through a photooxidative dehydrogenation reaction. The method is simple and efficient, and simultaneously activates its chemotherapy and photodynamic therapy activities. Dihydronitidine is used in cells and illuminated under oxygen conditions to achieve photoactivated fluorescence imaging in living cells. Through light control, the chemotherapy and photodynamic activities of the generated nitidine are utilized to achieve selective killing of cancer cells. In addition, based on the advantage of high spatiotemporal resolution of light, dihydronitidine can effectively improve the selective killing efficiency of cancer cells in an environment where cancer cells and normal cells coexist. The strategy of synergistic photoactivated chemotherapy and photodynamic therapy is of great value in promoting the medical application of nitidine. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The UV absorption spectrum, fluorescence emission spectrum and photodynamic activity diagram of compound ⅠⅠ-2; (A) is the normalized UV absorption spectrum of compound ⅠⅠ-1 in water (5*10 -5 mol·L -1 , left dotted line) and fluorescence emission spectra (5*10 - 5 mol·L -1, excitation wavelength is 380nm, solid line on the right); (B) fluorescence emission spectrum of compound ⅠⅠ-1 (1mM) in aqueous solution containing different concentrations (0, 100, 200, 400, 600, 800μM) of cucurbit[7]uril, with an excitation wavelength of 365nm; (C) is the ratio change diagram (I / I0) of the maximum emission intensity of compound ⅠⅠ-1 after combining with different concentrations of cucurbit[7]uril to the maximum emission intensity in aqueous solution under the test conditions of (B); wavelength change diagram corresponding to the maximum emission intensity of compound ⅠⅠ-1 after combining with different concentrations of cucurbit[7]uril; (D) compound ⅠⅠ-1 (1mM) generates reactive oxygen species under light, and reactive oxygen species induce the conversion of DCFH (10μM) probe into DCF with fluorescence enhancement dot-line diagram (excitation wavelength is 488nm, emission wavelength is 525nm).
[0029] Figure 2 The NMR hydrogen spectrum and carbon spectrum of compound I-1.
[0030] Figure 3 The photoactivated ultraviolet absorption spectra and fluorescence spectra of compounds I-1 and II-1 are shown in Figure 2; (A) is the photoactivated ultraviolet absorption spectra and fluorescence spectra of compound I-1 (5*10 -5 mol·L -1 ) in a mixed solution of water and dimethyl sulfoxide (95:5, v / v) and was illuminated by a portable UV lamp (365 nm, 5 mW / cm 2 ) is the UV absorption spectrum of compound I-1 after different illumination time; (B) is the ratio of the absorption peak intensity at 380nm to the initial intensity (A / A0) of compound I-1 under the test conditions of (A) as a function of illumination time; (C) is the UV absorption spectrum of compound I-1 (5*10 - 5 mol·L -1 ) in the presence of cucurbitacin[7]uril (5*10 -5 mol·L -1 ) of water and dimethyl sulfoxide (95:5, v / v) and a portable UV lamp (365 nm, 5 mW / cm 2 ) is the fluorescence spectra after different illumination times, with an excitation wavelength of 380 nm; (D) is the maximum fluorescence intensity of compound I-1 after different illumination times under the test conditions of (C), as a function of illumination time.
[0031] Figure 4The absorption spectra and electron cloud distribution diagrams of compounds I-1 and II-1; (A) is the theoretically calculated absorption spectrum and the measured absorption spectrum of compound I-1; (B) is the theoretically calculated absorption spectrum and the measured absorption spectrum of compound ⅠI-1; (C) is the electron cloud distribution diagram of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) of compound I-1; (D) is the electron cloud distribution diagram of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) of compound ⅠI-1.
[0032] Figure 5 The effects of compounds I-1 and II-1 on the cell viability of cervical cancer cells (HeLa); (A) is the cell viability of HeLa cancer cells after incubation with different concentrations of compound I-1 (0, 2, 4, 6, 8, 10, 20 μM) under light and dark conditions; (B) is the cell viability of HeLa cancer cells after incubation with different concentrations of compound I-1 (0, 2, 4, 6, 8, 10, 20 μM) under light and dark conditions; Illumination conditions: portable UV lamp (365 nm, 5 mW / cm 2 ) Expose to light for 10 minutes.
[0033] Figure 6 The effects of compounds I-1 and II-1 on cervical cancer cells (HeLa); (A) compounds I-1 and II-1 (10 -5 mol·L -1 ) is a confocal photograph of HeLa cells incubated with cervical cancer cells under laser (405nm, power: 2%) irradiation, 405nm laser, power 2%, fluorescence collection band 410-580nm; (B) is a confocal laser Lambda mode, compound I-1 and II-1 (10 -5 mol·L -1 ) fluorescence spectrum and laser confocal photograph of cervical cancer cells HeLa cells incubated with 405nm laser, power 2%, fluorescence collection band 410-580nm; (C) is compound I (10 -5 mol·L -1 ) After incubating cervical cancer cell HeLa cells and inducing cell apoptosis, the commercial apoptosis reagent Annexin FITC and PI stained cervical cancer cell HeLa cells with laser confocal fluorescence images, 405nm laser, 2% power, fluorescence collection band 410-580nm; (D) is compound ⅠI-1 (10 -5 mol·L -1) After incubating cervical cancer cell HeLa cells and inducing cell apoptosis, laser confocal fluorescence photographs of cervical cancer cell HeLa cells stained with commercial apoptosis reagents Annexin FITC and PI, Annexin FITC: 488nm laser, power 2%, fluorescence collection band 490-530nm; PI: 543nm laser, power 2%, fluorescence collection band 600-650nm.
[0034] Figure 7 Compound I-1(10 -5 mol·L -1 ) After incubating the coexistence of cervical cancer cells (HeLa) and mouse fibroblast normal cells (NIH-3T3), the laser confocal fluorescence photograph of cervical cancer cells (HeLa) was selectively illuminated (405nm, power: 10%), 405nm laser, and the fluorescence collection band was 410-580nm. DETAILED DESCRIPTION
[0035] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.
[0036] Example 1 Photooxidation to generate nitidine in situ
[0037] (1) Synthesis of the compound of formula Ⅰ-1:
[0038] The structural formula of compound I-1:
[0039]
[0040] Preparation of compound I-1:
[0041] Nitidine chloride (Compound II-1, 220 mg) was dissolved in methanol (30 mL), sodium borohydride (200 mg) was added, and the mixture was stirred at room temperature for 30 minutes. The precipitate was collected by filtration, washed with water, and dried to obtain an off-white solid product, dihydronitidine (50 mg, yield: 23%). The structural characterization related data are as follows:
[0042] 1 H NMR(d6-DMSO,400MHz):7.86(d,J=8.4Hz,1H),7.56(d,J=8.8Hz,1H),7.52(s,H),7.43(s,H ),7.31(s,H),6.97(s,H),6.13(s,2H),4.09(s,2H),3.87(s,3H),3.82(s,3H),3.49(s,3H); 13C NMR(d6-DMSO,100MHz):149.2,148.8,148.3,147.6,142.6,130.8,126.1,124.5,124 .5,124.4,124.0,120.7,111.1,107.3,104.7,101.6,100.2,56.3,56.0,54.3,41.2.
[0043] Figure 2 The following are the hydrogen and carbon NMR spectra of compound I-1.
[0044] (2) Photoactivated oxidative dehydrogenation of compound Ⅰ-1 to prepare nitidine:
[0045] Compound I-1 solution (10 μL, 10 mM, DMSO) was added to ultrapure water (100 μL) and a handheld UV lamp (365 nm, 5 mW / cm 2 ) for different time periods, then ultrapure water (890 μL) was added to dilute, and then the absorption spectrum was tested using a UV spectrophotometer. DHNC solution (10 μL, 10 mM, DMSO) was added to cucurbitacin[7]uril solution (100 μL, 1 mM, H2O), and a handheld UV lamp (365 nm, 5 mW / cm 2 ) for different periods of time, then ultrapure water (890 μL) was added for dilution, and then the fluorescence emission spectrum was tested using a fluorescence spectrometer with an excitation wavelength of 380 nm.
[0046] The structure of the natidine compound obtained by dehydrogenation is Formula II-1:
[0047]
[0048] X - Anions provided to the medium (hydroxyl in this example).
[0049] Under the irradiation of a portable UV lamp, the absorption intensity of the aqueous solution of compound I-1 at 380 nm increased continuously with the extension of the irradiation time, and reached equilibrium after 15 minutes of irradiation, indicating that compound I-1 can be efficiently converted into compound II-1 ( Figure 3 AB). At the same time, in the presence of cucurbitacin[7]uril, the fluorescence emission intensity at 504nm gradually increased with the extension of illumination time, further verifying that compound I-1 was transformed into compound II-1 through photooxidative dehydrogenation reaction, and was further encapsulated by cucurbitacin[7]uril, achieving fluorescence "lighting" ( Figure 3 CD).
[0050] Performance Testing:
[0051] Theoretical calculation of absorption spectra of compound I-1 and compound II-1
[0052] The B3LYP method in the density functional theory (DFT) of compound I-1 and compound II-1 monomers was used in the def2-TZVP basis set to optimize the geometry and calculate the frequency using the B3LYP method in the density functional theory (DFT) of Gaussian (v.16B01) software and considering the dispersion correction (D3BJ) with damping. Based on the obtained stable configuration, the absorption spectrum was calculated using the ωB97-XD method in the time-dependent density functional theory (TD-DFT) under the def2-TZVP basis set. All calculations used the PCM solvent model to simulate the aqueous solution environment during the experiment. The comparative analysis with the experimental spectrum was achieved using the SpecDis (v.1.71) software, in which the broadening was fitted by a Gaussian function, the default half-width parameter (σ) was 0.2 eV, and the molecular orbital distribution diagram was obtained using the default parameters of the Gaussview (v.6.0.16) software.
[0053] The absorption spectra of compound I-1 and compound II-1 were calculated and found that their maximum absorption peaks mainly come from the transition between the highest occupied orbital (HOMO) and the lowest unoccupied orbital (LUMO). The energy level difference is very close to the maximum absorption peak energy of the ultraviolet-visible light of the two in the experiment. The fitted absorption spectrum is compared with the experimental value. Figure 4 A and 4B. Figure 4 The electron cloud distribution of the HOMO and LUMO orbitals of C and 4D shows that compounds I-1 and II-1 exist as a mixture of localized states (LE) and intramolecular charge transfer states (ICT).
[0054] Example 2
[0055] The commercially available nitidine compound, compound II-2, has the following structural formula:
[0056]
[0057] Characterization of photophysical properties of compound ⅠI-2:
[0058] Figure 1 A is the normalized UV absorption spectrum and fluorescence emission spectrum of compound II-2 in water. Its maximum absorption wavelength is 380nm and its maximum emission wavelength is 524nm. Under the action of different concentrations of cucurbit[7]uril, the fluorescence of compound II-2 in aqueous solution gradually increases, and its maximum emission wavelength gradually blue-shifts to 515nm ( Figure 1 BC), which is mainly attributed to the restriction of intramolecular charge transfer process and intramolecular vibration.
[0059] Figure 1D is the ratio of the fluorescence intensity of DCFH and compound II-2 after being exposed to light for different time periods to the fluorescence intensity before exposure. 2',7'-Dichlorodihydrofluorescein (DCFH) is a reactive oxygen detection probe that can be oxidized by reactive oxygen to 2',7'-dichlorofluorescein (DCF) and emit yellow-green fluorescence. Within a certain range, the increase in fluorescence intensity is correlated with the amount of reactive oxygen produced. 500μL DCFH-DA solution (1mM, EtOH) was added with 2mL NaOH solution (10mM, H2O), and the reaction was carried out at room temperature in the dark for 30 minutes. 10mL PBS was added to adjust the pH value to neutral to obtain a DCFH mother solution with a final concentration of 40μM. Take 25μL DCFH mother solution and 10μL NC solution (10mM, DMSO), add 65μL PBS, and use a handheld UV lamp (365nm, 5mW / cm 2 ) After irradiation, the fluorescence emission intensity at 525nm was tested by an ELISA instrument, and the excitation wavelength was 488nm. The results showed that compound II-2 2 ), which can efficiently generate ROS( Figure 1 D). It can be seen that the compound has certain photodynamic activity.
[0060] Example 3
[0061] Application of dihydronitidine in cancer treatment
[0062] Cervical cancer cells (HeLa) in the logarithmic growth phase were digested and 4 The cells were inoculated in a 96-well plate at a density of 100 cells / well, with 5 replicate wells in each group. A blank control group (only culture medium) was also set up. After 24 hours of culture, different concentrations of compound I-1 or compound II-1 were added and incubated for 4 hours. A handheld UV lamp (365 nm, 5 mW / cm 2 ) for 10 minutes, and then continue to incubate for 24 hours. 100 μL of MTT solution (0.5 mg / mL, 90% DMEM + 10% PBS) was added to each well, and then incubated for 4 hours. 100 μL of DMSO was added, and the cells were shaken for 10 minutes. The absorbance at 570 nm was measured using an enzyme-labeled instrument.
[0063] The cell survival rate experiment showed that compound II-1 had obvious dark toxicity to cells. When the incubation concentration was 10 μM, the cell survival rate was 47%. After illumination, due to the generation of reactive oxygen species, its cytotoxicity was further enhanced, and the cell survival rate dropped to 32%. This indicates that compound II-1 has both chemotherapeutic and photodynamic therapeutic activities ( Figure 5A). In contrast, compound I-1 has little dark toxicity to cells, with a cell survival rate of more than 90%, and has good biocompatibility, while its cytotoxicity increases significantly after illumination ( Figure 5 B), the cell survival rate dropped to 45%, which was due to the in situ conversion of compound I-1 into compound II-1, which could effectively improve the killing efficiency of cancer cells by in situ activating its chemotherapeutic and photodynamic activities.
[0064] Example 4
[0065] Application of dihydronitidine in cell fluorescence imaging and cancer therapy
[0066] HeLa cells in the logarithmic growth phase were digested and 5 The cells were inoculated in a confocal dish at a density of 100 cells / dish and cultured for 24 hours. 1 ml of culture solution containing 10 μM compound I-1 or compound II-1 was added and incubated for 1 hour. Laser confocal imaging was used to observe and activate compound I-1 or compound II-1 in the cells. The results showed that the cells stained with compound I-1 alkali had almost no fluorescence at the beginning. Only under 405nm laser irradiation, the orange fluorescence gradually increased and gradually enriched in the cell nucleus. For cells stained with compound II-1, orange fluorescence can be observed to be rapidly emitted in the mitochondria. After 405nm laser irradiation, the orange fluorescence gradually enriched in the cell nucleus ( Figure 6 A), the experimental results show that compound I-1 is effectively converted into nitidine under light, further enriched in the cell nucleus and inserted into the base pairs of nucleic acids, thereby "lighting up" orange fluorescence. Further, through the Lambda scanning mode of laser confocal microscopy, it was observed that the fluorescence spectrum of compound I-1 after being activated by light was consistent with the fluorescence spectrum of the cell nucleus directly incubated with compound II-1 ( Figure 6 B), further confirming that compound I-1 was transformed into compound II-1 under laser irradiation.
[0067] Cervical cancer cells (HeLa) in the logarithmic growth phase were digested and 5 The cells were inoculated in a confocal dish at a density of 100 cells / dish and cultured for 24 hours. 1 ml of culture solution containing 10 μM compound I-1 or compound II-1 was added and incubated for 1 hour. After irradiating the cells with a 405nm laser at a power of 2% for 5 minutes, 10 μL of apoptosis staining reagents Annexin FITC and PI were added in situ, incubated in the dark for 30 minutes, and then imaged and observed under a laser confocal microscope. The results showed that after 5 minutes of 405nm laser irradiation of compound I-1 and compound II-1, the cell surface was obviously blistering ( Figure 6 A), and then the cells were stained with commercial apoptosis reagents Annexin FITC and PI ( Figure 6CD), found that after 405nm laser irradiation for 5 minutes and incubation in the dark for 30 minutes, Annexin FITC can stain the cell membrane, and PI staining can stain the cell nucleus, proving that the cells are in a late apoptotic state. The experimental results show that compound I-1 can be converted into compound II-1 under light, thereby activating the chemotherapy and photodynamic activity of compound II-1, and the two synergistically induce cancer cell apoptosis.
[0068] Example 5
[0069] Highly spatially selective photoactivation to kill cancer cells
[0070] Cervical cancer cells (HeLa) and normal mouse fibroblasts (NIH-3T3) in the logarithmic growth phase were digested and incubated at 5 × 10 4 The cells were inoculated at a density of 100 cells / dish on the same confocal dish and cultured for 24 hours. 1 ml of culture medium containing 10 μM compound I-1 was added and incubated for 1 hour. Laser confocal microscopy was used for imaging and selective illumination of cervical cancer cells (HeLa). The results showed that in the coexistence of HeLa cancer cells and NIH-3T3 normal cells, selective illumination of the HeLa cancer cell area not only "lit up" the orange fluorescence in the nucleus of HeLa cancer cells, but also effectively induced obvious blistering on the surface of HeLa cancer cells, while NIH-3T3 normal cells had no obvious fluorescence and morphological changes ( Figure 7 ), indicating that the photoactivated compound I-1 can achieve high spatial selectivity in killing cancer cells and reduce the toxic side effects on normal cells.
[0071] The invention establishes a simple and efficient preparation method of dihydronitidine and nitidine. Dihydronitidine can undergo photooxidative dehydrogenation reaction under light to generate nitidine with chemotherapy and photodynamic activity, thereby achieving high spatial selectivity in killing cancer cells.
[0072] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A method for photoactivated in-situ generation of nitidine, characterized in that: 100 μL of ultrapure water was added to 10 μL of 10 mM DMSO solution of dihydronitidine represented by formula (I) and a handheld UV lamp at 365 nm and 5 mW / cm 2 , light exposure for 15 min; The structure of nitidine is X is a hydroxyl group.
